Nifty
Sensex
:
:
13258.55
45079.55
124.65 (0.95%)
446.90 (1.00%)

Pharmaceuticals & Drugs - Global

Rating :
56/99

BSE: 524816 | NSE: NATCOPHARM

920.00
04-Dec-2020
  • Open
  • High
  • Low
  • Previous Close
  •  920.00
  •  926.80
  •  908.25
  •  918.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  218554
  •  2001.56
  •  996.00
  •  402.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,725.62
  • 31.93
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,975.52
  • 0.74%
  • 4.11

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.91%
  • 1.53%
  • 14.86%
  • FII
  • DII
  • Others
  • 19.32%
  • 12.91%
  • 2.47%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.34
  • 10.91
  • -4.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.46
  • 16.40
  • -8.90

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.02
  • 24.01
  • -12.85

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 29.38
  • 26.18
  • 20.75

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.31
  • 5.50
  • 3.83

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.90
  • 21.17
  • 15.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
802.20
485.70
65.16%
563.40
492.30
14.44%
454.80
455.70
-0.20%
482.20
556.70
-13.38%
Expenses
525.80
351.40
49.63%
392.30
301.00
30.33%
326.50
307.40
6.21%
353.50
348.30
1.49%
EBITDA
276.40
134.30
105.81%
171.10
191.30
-10.56%
128.30
148.30
-13.49%
128.70
208.40
-38.24%
EBIDTM
34.46%
27.65%
30.37%
38.86%
14.01%
32.54%
26.69%
37.43%
Other Income
25.70
33.20
-22.59%
18.70
21.00
-10.95%
22.40
31.00
-27.74%
30.80
23.30
32.19%
Interest
2.70
6.20
-56.45%
3.70
6.50
-43.08%
3.50
5.20
-32.69%
5.30
6.30
-15.87%
Depreciation
28.70
21.90
31.05%
28.00
22.00
27.27%
30.50
21.70
40.55%
25.40
20.70
22.71%
PBT
270.70
139.40
94.19%
158.10
183.80
-13.98%
116.70
152.40
-23.43%
128.80
204.70
-37.08%
Tax
66.80
21.70
207.83%
36.00
41.00
-12.20%
23.50
32.00
-26.56%
24.40
45.40
-46.26%
PAT
203.90
117.70
73.24%
122.10
142.80
-14.50%
93.20
120.40
-22.59%
104.40
159.30
-34.46%
PATM
25.42%
24.23%
21.67%
29.01%
7.11%
26.42%
21.65%
28.62%
EPS
11.19
6.46
73.22%
6.70
7.84
-14.54%
5.12
6.61
-22.54%
5.73
8.74
-34.44%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
2,302.60
1,915.00
2,094.50
2,184.80
2,020.20
1,141.30
825.28
738.89
660.53
523.72
459.68
Net Sales Growth
15.69%
-8.57%
-4.13%
8.15%
77.01%
38.29%
11.69%
11.86%
26.12%
13.93%
 
Cost Of Goods Sold
5,109.40
354.40
332.70
411.10
599.10
341.10
242.37
233.23
242.80
203.08
186.08
Gross Profit
-2,806.80
1,560.60
1,761.80
1,773.70
1,421.10
800.20
582.90
505.67
417.73
320.64
273.60
GP Margin
-121.90%
81.49%
84.12%
81.18%
70.34%
70.11%
70.63%
68.44%
63.24%
61.22%
59.52%
Total Expenditure
1,598.10
1,332.40
1,299.70
1,256.40
1,336.80
868.70
611.90
559.56
510.60
414.38
369.11
Power & Fuel Cost
-
62.40
59.60
56.20
50.50
43.70
43.24
44.77
38.75
26.88
21.41
% Of Sales
-
3.26%
2.85%
2.57%
2.50%
3.83%
5.24%
6.06%
5.87%
5.13%
4.66%
Employee Cost
-
375.00
355.90
325.60
243.20
189.60
136.92
112.77
102.29
80.05
66.39
% Of Sales
-
19.58%
16.99%
14.90%
12.04%
16.61%
16.59%
15.26%
15.49%
15.28%
14.44%
Manufacturing Exp.
-
243.30
276.40
182.60
141.20
105.20
73.04
76.57
65.10
43.32
40.18
% Of Sales
-
12.70%
13.20%
8.36%
6.99%
9.22%
8.85%
10.36%
9.86%
8.27%
8.74%
General & Admin Exp.
-
132.80
126.40
105.50
88.10
73.40
63.66
56.21
39.49
32.37
27.32
% Of Sales
-
6.93%
6.03%
4.83%
4.36%
6.43%
7.71%
7.61%
5.98%
6.18%
5.94%
Selling & Distn. Exp.
-
98.10
90.00
136.90
143.20
91.60
37.36
26.16
14.82
19.02
13.24
% Of Sales
-
5.12%
4.30%
6.27%
7.09%
8.03%
4.53%
3.54%
2.24%
3.63%
2.88%
Miscellaneous Exp.
-
66.40
58.70
38.50
71.50
24.10
15.31
9.85
7.36
9.66
13.24
% Of Sales
-
3.47%
2.80%
1.76%
3.54%
2.11%
1.86%
1.33%
1.11%
1.84%
3.15%
EBITDA
704.50
582.60
794.80
928.40
683.40
272.60
213.38
179.33
149.93
109.34
90.57
EBITDA Margin
30.60%
30.42%
37.95%
42.49%
33.83%
23.89%
25.86%
24.27%
22.70%
20.88%
19.70%
Other Income
97.60
107.40
130.20
40.40
13.90
9.90
14.91
16.71
12.41
9.14
4.64
Interest
15.20
21.50
19.30
15.40
18.50
22.90
31.68
36.62
26.31
23.04
14.20
Depreciation
112.60
99.80
81.00
66.20
54.40
51.00
47.27
30.44
22.12
15.91
15.88
PBT
674.30
568.70
824.70
887.20
624.40
208.60
149.34
128.98
113.90
79.54
65.12
Tax
150.70
110.60
182.30
192.00
139.50
52.80
3.95
30.87
36.44
21.07
13.21
Tax Rate
22.35%
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
23.93%
35.61%
26.49%
20.29%
PAT
523.60
460.80
644.40
696.20
486.00
157.10
134.62
102.74
71.87
59.61
53.51
PAT before Minority Interest
522.90
458.10
642.40
695.20
484.90
155.80
130.27
98.11
65.88
58.47
51.91
Minority Interest
-0.70
2.70
2.00
1.00
1.10
1.30
4.35
4.63
5.99
1.14
1.60
PAT Margin
22.74%
24.06%
30.77%
31.87%
24.06%
13.77%
16.31%
13.90%
10.88%
11.38%
11.64%
PAT Growth
-3.07%
-28.49%
-7.44%
43.25%
209.36%
16.70%
31.03%
42.95%
20.57%
11.40%
 
EPS
28.74
25.29
35.37
38.21
26.67
8.62
7.39
5.64
3.94
3.27
2.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
3,773.50
3,489.00
3,072.20
1,649.30
1,295.70
846.05
725.88
533.54
473.63
352.43
Share Capital
36.40
36.50
36.90
34.90
34.80
33.23
33.07
31.37
31.15
28.15
Total Reserves
3,713.60
3,421.70
3,011.40
1,599.00
1,251.20
812.82
692.80
502.17
442.49
324.29
Non-Current Liabilities
117.80
83.40
47.10
37.70
28.00
119.23
150.67
191.46
171.34
160.44
Secured Loans
0.00
0.00
0.00
0.00
0.00
94.03
92.20
135.62
133.88
125.21
Unsecured Loans
0.90
0.00
0.00
0.00
0.00
2.99
3.28
2.21
0.22
0.22
Long Term Provisions
90.20
71.00
32.40
21.90
12.50
9.50
11.09
8.62
6.59
8.67
Current Liabilities
685.30
728.70
592.00
626.50
493.10
413.74
312.28
344.87
259.35
193.38
Trade Payables
255.40
217.00
269.10
262.70
275.60
125.30
109.79
105.85
92.36
76.60
Other Current Liabilities
95.90
109.80
133.40
127.10
114.20
118.56
102.18
90.21
81.91
43.86
Short Term Borrowings
315.00
386.30
173.20
221.60
98.40
168.54
98.63
147.74
81.64
72.02
Short Term Provisions
19.00
15.60
16.30
15.10
4.90
1.33
1.69
1.07
3.44
0.91
Total Liabilities
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.41
905.20
707.31
Net Block
1,584.40
1,227.20
1,018.60
833.00
710.10
709.97
644.74
582.75
319.56
270.16
Gross Block
2,148.60
1,694.50
1,407.60
1,158.70
983.30
939.98
819.89
726.97
440.33
374.37
Accumulated Depreciation
564.20
467.30
389.00
325.70
273.20
225.82
171.11
140.57
117.34
104.21
Non Current Assets
2,262.20
1,955.90
1,584.40
1,230.30
984.70
901.08
827.57
749.94
612.42
460.37
Capital Work in Progress
518.00
637.60
480.00
336.30
211.80
128.96
123.78
105.84
164.43
75.98
Non Current Investment
83.60
19.90
8.10
0.10
0.10
1.57
1.57
1.54
61.79
61.79
Long Term Loans & Adv.
72.00
62.80
75.40
60.40
62.10
57.03
54.25
57.20
66.22
51.49
Other Non Current Assets
4.20
8.40
2.30
0.50
0.60
3.54
3.24
2.61
0.42
0.96
Current Assets
2,325.60
2,347.20
2,130.70
1,087.30
837.00
482.97
368.14
330.48
292.79
246.95
Current Investments
28.70
148.70
68.40
32.10
22.10
0.12
0.32
0.81
0.74
0.82
Inventories
558.00
529.00
438.40
348.90
357.30
220.00
181.12
146.02
110.39
102.23
Sundry Debtors
551.30
506.20
637.50
475.20
261.60
192.43
118.80
129.71
94.69
70.98
Cash & Bank
66.00
279.50
183.70
35.80
45.20
13.36
11.05
10.78
36.63
32.37
Other Current Assets
1,121.60
107.40
53.20
25.80
150.80
57.06
56.85
43.14
50.34
40.55
Short Term Loans & Adv.
1,030.00
776.40
749.50
169.50
125.40
40.97
52.46
38.85
41.84
36.73
Net Current Assets
1,640.30
1,618.50
1,538.70
460.80
343.90
69.23
55.85
-14.39
33.44
53.56
Total Assets
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.42
905.21
707.32

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
417.30
668.80
463.60
345.80
112.20
92.67
144.03
61.19
64.94
36.99
PBT
568.70
824.70
887.20
624.40
208.60
134.22
128.98
102.32
79.54
65.12
Adjustment
54.00
14.30
75.60
100.20
90.50
68.14
65.72
48.87
36.97
38.87
Changes in Working Capital
-97.60
8.60
-294.60
-253.00
-140.70
-85.96
-16.11
-67.39
-27.97
-48.50
Cash after chg. in Working capital
525.10
847.60
668.20
471.60
158.40
116.41
178.58
83.80
88.54
55.49
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-107.80
-178.80
-204.60
-125.80
-46.20
-23.74
-34.55
-22.61
-23.60
-18.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-167.00
-612.20
-1,115.50
-299.40
-175.50
-114.75
-108.92
-107.07
-126.94
-88.78
Net Fixed Assets
-335.80
-436.10
-392.40
-299.40
-303.91
-100.13
-99.70
-102.47
-151.51
-71.49
Net Investments
53.30
-94.80
-54.80
-1.00
37.47
-42.37
-11.33
-2.67
-3.71
8.04
Others
115.50
-81.30
-668.30
1.00
90.94
27.75
2.11
-1.93
28.28
-25.33
Cash from Financing Activity
-250.80
-50.90
650.90
-47.70
154.00
29.07
-35.27
26.31
62.78
77.10
Net Cash Inflow / Outflow
-0.50
5.70
-1.00
-1.30
90.70
6.99
-0.15
-19.57
0.78
25.31
Opening Cash & Equivalents
28.30
21.70
23.50
24.20
-164.10
10.22
9.95
34.64
31.70
6.53
Closing Cash & Equivalent
19.80
28.30
21.70
23.50
-74.20
12.44
10.22
9.95
34.64
31.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
206.04
189.49
165.22
93.63
73.91
50.91
219.48
170.06
152.06
125.21
ROA
10.30%
16.02%
23.05%
23.43%
9.72%
10.10%
8.62%
6.64%
7.25%
8.23%
ROE
12.71%
19.75%
29.70%
33.21%
14.62%
16.57%
15.58%
13.08%
14.16%
15.77%
ROCE
14.82%
23.71%
35.28%
39.21%
18.04%
15.62%
18.02%
16.04%
15.72%
15.90%
Fixed Asset Turnover
1.07
1.47
1.72
1.93
1.23
0.95
0.96
1.14
1.30
1.27
Receivable days
93.77
91.36
92.22
65.12
70.27
67.76
60.90
61.30
56.98
50.31
Inventory Days
96.38
77.28
65.25
62.41
89.35
87.33
80.17
70.04
73.13
70.50
Payable days
65.96
72.53
81.42
78.30
85.42
73.36
74.09
73.36
79.03
83.93
Cash Conversion Cycle
124.19
96.11
76.05
49.23
74.21
81.73
66.99
57.98
51.07
36.89
Total Debt/Equity
0.08
0.11
0.06
0.14
0.09
0.37
0.33
0.63
0.55
0.62
Interest Cover
27.45
43.73
58.61
34.75
10.11
5.24
4.52
4.89
4.45
5.59

News Update:


  • Natco Pharma’s marketing partner gets USFDA’s final nod for Pomalidomide Capsules
    13th Nov 2020, 11:45 AM

    Pomalyst had annual sales of $957 million during the twelve months ending September 2020

    Read More
  • Natco Pharma reports 70% rise in Q2 consolidated net profit
    12th Nov 2020, 16:32 PM

    Total income of the company increased by 59.55% at Rs 827.90 crore for Q2FY21

    Read More
  • Natco Pharma aims to launch around 10 new products every year in Indian market
    16th Oct 2020, 09:15 AM

    It has also some interesting filings and high-value launches in its international markets in the coming years

    Read More
  • Natco Pharma aims to diversify product portfolio in domestic market
    21st Sep 2020, 17:15 PM

    The company is planning for new product launches in the non-oncology segment to mitigate the impact of the Hepatitis-C market decline

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.